Haemonetics Corporation (HAE) fundamentals score
Haemonetics believes that Plasma and Hospital have the greatest growth potential and are well positioned to drive long-term value. Blood Center operates in more challenging markets, and it has sharpened its focus accordingly on targeted opportunities – particularly in plasma and platelets – while ensuring continued alignment of this business with the Company’s broader strategic objectives.
Surgical & Medical Instruments & Apparatus · Healthcare · Listed on NYSE
Overall: 6.2 out of 10, Mixed fundamentals
- Growth: 4.6/10
- Profitability: 5.8/10
- Financial health: 7.3/10
- Earnings quality: 9.7/10
- Valuation: 4.4/10
Scores are calculated from Haemonetics Corporation’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10